Sign in

You're signed outSign in or to get full access.

Acuta Capital Partners, LLC

CIK:0001582844
Hedge Fund
$154M AUM
28 holdings
Belmont, CA, United States
Founded:2011
5 employees
Latest filing:Jun 30, 2025

Acuta Capital Partners, LLC is an investment management firm headquartered in Belmont, California, United States. Founded in 2011 and primarily owned by Anupam Dalal, who serves as Managing Member, the firm specializes in providing investment advisory services. With approximately 5 employees, Acuta Capital Partners operates pooled investment vehicles and serves accredited institutional clients and high-net-worth individuals.

Investment Strategy

Acuta Capital Partners focuses on managing pooled investment vehicles, investing in publicly traded equities with an emphasis on healthcare and biotechnology sectors. The firm utilizes fundamental analysis and a long/short equity strategy, aiming to generate absolute returns while managing downside risk. Investment decisions are based on intensive research and bottom-up analysis, frequently targeting innovative companies in life sciences and therapeutics.

Latest 13F Filing Activity

Acuta Capital Partners, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 26 equity positions with a total 13F market value of $72M. The fund increased holdings in Cidara Therapeutics Inc., Jazz Pharmaceuticals PLC, Taysha Gene Therapies Inc. among other positions. Acuta Capital Partners, LLC reduced exposure to Enliven Therapeutics Inc., Insmed Inc., Trevi Therapeutics Inc. among others.

Top Buys
C
CDTXCIDARA THERAPEUTICS INC
+$6.0M
J
JAZZJAZZ PHARMACEUTICALS PLC
+$1.6M
T
TSHATAYSHA GENE THERAPIES INC
+$1.1M
A
AKROAKERO THERAPEUTICS INC
+$1.1M
T
TERNTERNS PHARMACEUTICALS INC
+$831.7K
Top Sells
E
ELVNENLIVEN THERAPEUTICS INC
-$5.2M
I
INSMINSMED INC
-$4.4M
T
TRVITREVI THERAPEUTICS INC
-$2.2M
M
MRKMERCK & CO
-$2.1M
T
TRMLTOURMALINE BIO INC
-$2.0M

Top Holdings

O
OCULOCULAR THERAPEUTIX INC
+13.1%$9.4M
C
CDTXCIDARA THERAPEUTICS INC
+12.2%$8.7M
A
AADIWHITEHAWK THERAPEUTICS INC
+8.9%$6.4M
S
SLNOSOLENO THERAPEUTICS INC
+7.4%$5.3M
T
TRMLTOURMALINE BIO INC
+6.3%$4.5M

Equity Positions (26)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
OCULAR THERAPEUTIX INC13.15%$9.4M1,014,940$6.66$9.28+$478.1K
CIDARA THERAPEUTICS INC12.21%$8.7M179,569$31.31$48.71+$6.0M
WHITEHAWK THERAPEUTICS INC8.90%$6.4M3,410,402$15.31$1.71+$306.9K
SOLENO THERAPEUTICS INC7.42%$5.3M63,436$71.45$83.78+$517.8K
TOURMALINE BIO INC6.33%$4.5M283,682$23.46$15.99-$2.0M

Industry Allocation

PHARMACEUTICAL PREPARATIONS
+57.1%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+42.6%

Investment Team (3)

NameRoleLocationLinkedIn
J
James P.
Acuta Capital PartnersUnited States
Kevin Hong
Kevin Hong
AnalystSan Jose, CA , United States
Paul Dellorusso
Paul Dellorusso
AnalystNew York, NY , United States